Regulus Therapeutics (NASDAQ: RGLS) reported Q1 EPS of ($0.08), $0.01 better than the analyst estimate of ($0.09).

"We are excited about the data we recently announced from the first cohort of our phase 1b clinical trial of RGLS4326 for the treatment of patients with ADPKD where we saw mean increases of greater than 50% and 20% in Polycystin 1 (PC1) and Polycystin 2 (PC2), respectively. PC1 and PC2 are the products of the PKD1 and PKD2 genes, and are depressed in patients with this disease. The trends for both suggest that with continued therapy, higher levels of these proteins may be attainable and less frequent dosing required. Additionally, RGLS4326 was well tolerated by all nine patients with no serious adverse events reported", stated Jay Hagan, CEO of Regulus. "Data from the first cohort provides the safety and pharmacokinetic data needed to complete the modeled safety margins. We plan to submit these data to FDA this summer in the context of our discussions regarding the remaining partial clinical hold requirements."

For earnings history and earnings-related data on Regulus Therapeutics (RGLS) click here.